Patents by Inventor Susanna Tchilibon
Susanna Tchilibon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8981095Abstract: The present invention relates to a process for the preparation of Lurasidone or a pharmaceutically acceptable salt thereof, a compound useful for the treatment of schizophrenia and bipolar disorder. The present invention further relates to processes for the preparation of Lurasidone intermediates, and to certain novel intermediates obtained by such processes.Type: GrantFiled: June 13, 2012Date of Patent: March 17, 2015Assignee: Mapi Pharma Ltd.Inventors: Ehud Marom, Michael Mizhiritskii, Susanna Tchilibon, Shai Rubnov
-
Publication number: 20140179922Abstract: The present invention relates to a process for the preparation of Lurasidone or a pharmaceutically acceptable salt thereof, a compound useful for the treatment of schizophrenia and bipolar disorder. The present invention further relates to processes for the preparation of Lurasidone intermediates, and to certain novel intermediates obtained by such processes.Type: ApplicationFiled: June 13, 2012Publication date: June 26, 2014Applicant: MAPI PHARMA LTD.Inventors: Ehud Marom, Michael Mizhiritskii, Susanna Tchilibon, Shai Rubnov
-
Publication number: 20110150820Abstract: Conjugates of polypeptides and a polymeric moiety such as PEG covalently attached to the sulfur atom of a methionine side chain are disclosed. Processes of preparing such conjugates, including intermediates and reagents utilized therefore are also disclosed. Further disclosed are therapeutic uses of these conjugates.Type: ApplicationFiled: August 27, 2009Publication date: June 23, 2011Applicant: Insight Biopharmaceuticals Ltd.Inventors: Joel M. Van Gelder, Andrei Serban, Susanna Tchilibon, Daphna Miron
-
Patent number: 7825126Abstract: Disclosed are (N)-methanocarba adenine nucleosides of the formula: as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.Type: GrantFiled: September 2, 2005Date of Patent: November 2, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kenneth A. Jacobson, Bhalchandra V. Joshi, Susanna Tchilibon
-
Patent number: 7795255Abstract: Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.Type: GrantFiled: January 5, 2006Date of Patent: September 14, 2010Assignee: InSight Biopharmaceuticals Ltd.Inventors: Joel M. Van Gelder, Joseph Y. Klein, Yochai Basel, Anat Reizelman, Susanna Tchilibon, Orly Mouallem
-
Publication number: 20080039456Abstract: Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.Type: ApplicationFiled: January 5, 2006Publication date: February 14, 2008Inventors: Joel Gelder, Joseph Klein, Yochai Basel, Anat Reizelman, Susanna Tchilibon, Orly Mouallem
-
Publication number: 20070232626Abstract: Disclosed are (N)-methanocarba adenine nucleosides of the formula: [Formula] as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.Type: ApplicationFiled: September 2, 2005Publication date: October 4, 2007Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HInventors: Kenneth Jacobson, Bhalchandra Joshi, Susanna Tchilibon
-
Patent number: 7214716Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)- type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: GrantFiled: January 27, 2005Date of Patent: May 8, 2007Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Publication number: 20050165118Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: ApplicationFiled: January 27, 2005Publication date: July 28, 2005Applicant: YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Patent number: 6903137Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: GrantFiled: April 26, 2002Date of Patent: June 7, 2005Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Patent number: 6864291Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: GrantFiled: October 30, 2000Date of Patent: March 8, 2005Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Publication number: 20020173528Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: ApplicationFiled: April 26, 2002Publication date: November 21, 2002Inventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon